CVS holds off adding Gilead’s new HIV prevention shot to drug coverage lists

Reuters reported exclusively that CVS Health, which runs the largest U.S. pharmacy benefit manager, will not add Gilead Sciences’ new HIV prevention drug Yeztugo to its

commercial plans for now, despite the medicine’s proven effectiveness. The story ran Wednesday after the close, and Gilead shares opened 2.6% lower on Thursday.